semaglutide early pregnancy and Pregnancy: Safety Guide for Planning Parents Discontinuing GLP-1s Before or Early

GLP-1 prescriptions grew from ~9M in Q4 2022 (source) to ~24M by Q4 2024 (source)

For example, Novos primary semaglutide patent is set to expire in 2026 in Canada and China

10.1093/eurjpc/zwae379 136

Because retatrutide is investigational and not FDA approved, licensed pharmacies cannot legally compound or dispense it

Week 4 12 The protocol starts to settle This is when most patients begin to feel the treatment working more consistently

Clinical Context Relevant to GLP-1 Treatment Discussions in 2026 GLP-1 receptor agonists like semaglutide represent a class of medications originally developed for type 2 diabetes management that have demonstrated meaningful effects on weight management in clinical research